Ricevi le ultime notizie sulle azioni Dare Bioscience con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di DARE

Ultime notizie per

DARE BIOSCIENCE INC

Dare Bioscience

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Wall-street-shutter3

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DARE

EDHL

FAST

HTOO

NEGG

SONN

SQFT

Wall Street mostra un calo nella mattinata USA con Dow Jones, NASDAQ e S&amp;P 500 in ribasso; comunicazioni in verde, energetico in affanno.

Wall Street segna un trend ribassista con Dow Jones e Nasdaq in flessione

Dare Bioscience Inc

Health Care

Press Releases

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends "FOCUSfactor" Exploding Across North America – More Stocks Inside

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Earnings

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Financing

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

AMZN

COST

PNPNF

SNYR

TSXV:PNPN

WOLF

AN2 Therapeutics

Aytu BioPharma

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Incannex Healthcare

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

PolyPid

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

SCYNEXIS

SenesTech

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Maxim Group

HC Wainwright & Co.

Jones Trading

Brookline Capital

JonesTrading

Comments

Dare Bioscience Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO